Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinationsElectronic supplementary information (ESI) available: Tables S1-S3 and Fig. S1-S3. See DOI: 10.1039/c4mb00610k
Targeting mitotic regulation is recognized as an important strategy for cancer therapy. Aurora A/B kinase and polo-like kinase 1 (PLK1) are the key mitotic regulators, and many inhibitors have been developed. Combinations of these inhibitors are anticipated to be more effective therapeutics compared...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Journal Article |
Language | English |
Published |
20.01.2015
|
Online Access | Get full text |
Cover
Loading…
Summary: | Targeting mitotic regulation is recognized as an important strategy for cancer therapy. Aurora A/B kinase and polo-like kinase 1 (PLK1) are the key mitotic regulators, and many inhibitors have been developed. Combinations of these inhibitors are anticipated to be more effective therapeutics compared with single-inhibitor treatments; however, a systematic analysis of the combined effects is lacking. Here, we constructed the first mammalian cell mitotic regulation network model, which spans from mitotic entry to anaphase initiation, and contains all key mitotic kinase targets. The combined effects of different kinase inhibitors and microtubule inhibitors were systematically explored. Simultaneous inhibition of Aurora B and PLK1 strongly induces polyploidy. Microtubule inhibitor dosage can be significantly reduced when combined with a PLK1 inhibitor. The efficacy of these inhibitor combinations was validated by our experimental results. The mitotic regulatory network model provides a platform to study the complex interactions during mitosis, enables identification of mitotic regulators, and determines targets for drug discovery research. The suggested use of combining microtubule inhibitors with PLK1 inhibitors is anticipated to enhance microtubule-inhibitor tolerance in a wide range of patients.
A mammalian cell mitotic network model was built and two effective anti-cancer drug combinations, Aurora B/PLK1 and microtubule formation/PLK1, were identified. |
---|---|
Bibliography: | Electronic supplementary information (ESI) available: Tables S1-S3 and Fig. S1-S3. See DOI 10.1039/c4mb00610k |
ISSN: | 1742-206X 1742-2051 |
DOI: | 10.1039/c4mb00610k |